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Abstract
Background: Noninvasive ventilation (NIV) has proved to be a useful technique for breathing support. However,
complications, discomfort, and failure of NIV were commonly caused by the mask. Therefore, the helmet was
developed to improve performance and reduce complications; however, there has been no conclusive results on its
effect until now. Thus, we performed a systematic review and meta-analysis to investigate the effect of NIV with a
helmet versus the control strategy in patients with acute respiratory failure (ARF).
Methods: We searched Cochrane Library, PubMed, Ovid, and Embase databases and bibliographies of relevant
articles published before June 2016. Randomized and case-control studies that adopted the helmet as an NIV
interface and compared it with another interface were included. The primary outcomes were hospital mortality,
intubation rate, and complications. The secondary outcomes included the length of intensive care unit (ICU) stay,
gas exchange, and respiratory rate. Pooled odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated by
the Mantel-Haenszel method and mean difference by the inverse variance method in a fixed effect model or
random effects model according to the heterogeneity.
Results: A total of 11 studies involving 621 patients were included. The overall hospital mortality was 17.53 % in
the helmet NIV group versus 30.67 % in the control group. Use of the helmet was associated with lower hospital
mortality (OR 0.43, 95 % CI 0.26 to 0.69, p = 0.0005), intubation rate (OR 0.32, 95 % CI 0.21 to 0.47, P < 0.00001), and
complications (OR 0.6, 95 % CI 0.4 to 0.92, P = 0.02). In contrast, there was no significant difference in gas exchange
and ICU stay (P >0.05). Subgroup analysis found the helmet reduced mortality mainly in hypoxemic ARF patients
(P < 0.05) and a lower intubation rate was shown in randomized trials; fewer complications caused by the helmet
might be restricted to case-control trials. Additionally, the effect of the helmet on PaCO2 was influenced by type of
ARF and ventilation mode (P <0.00001).
Conclusion: NIV with a helmet was associated with reduced hospital mortality and intubation requirement. The
helmet was as effective as the mask in gas exchange with no additional advantage. Large randomized controlled
trials are needed to provide more robust evidence.
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Background
Noninvasive ventilation (NIV) has proved to be a useful
technique for breathing support that improved gas ex-
change and reduced the need for intubation and mortal-
ity in patients with exacerbation of chronic obstructive
pulmonary disease, acute cardiogenic pulmonary edema,
and blunt chest trauma [1–4]. However, the overall fail-
ure of NIV occurred in 16–30 % of patients [5, 6], which
depended on not only the underlying cause of acute re-
spiratory failure (ARF) and the severity of the patients’
disease, but also the multiple technical causes including
interface-associated complications [7, 8].
The mask turned mechanical ventilation without in-
tubation into reality and was a key success factor in
NIV. Despite great improvements in the material quality,
shape, size, and fixing system of the mask, complications
such as skin lesions, nasal pain, ulcerations of the nose
bridge, and discomfort were very common [7, 9, 10].
NIV might fail in 18 % of cases attributable to mask dis-
comfort [11], and failure of facial mask-delivered NIV
was associated with a threefold increase in hospital mor-
tality [12]. In an attempt to improve performance and
reduce complications, the helmet was developed, which
was a new-fashioned interface with the advantage of
avoiding skin lesions and improving patient comfort in-
dependent of face morphology [13, 14]. Nevertheless,
there has been no clear consensus on its effect until
now. Whether NIV delivered by helmet could reduce
the intubation rate and mortality was still causing contro-
versy [15, 16], furthermore, the effect on gas exchange was
also confusing. Some studies indicated NIV delivered by
helmet could improve oxygenation further compared with
a face mask [17, 18], while others showed there was no
significant difference in oxygenation [19–21], and some
studies even demonstrated helmet-induced carbon dioxide
rebreathing [22].
Therefore, we conducted a meta-analysis to investigate
the effect of NIV with a helmet on hospital mortality, in-
tubation rate, complications, and gas exchange versus
the control strategy in patients with ARF.
Methods
This systematic review and meta-analysis was performed
in adherence to the recently published Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement [23] and our prespecified protocol.
Ethical approval and patient consent were not required
since this was a meta-analysis of previously published
studies. The eligible participants were adults (at least
18 years old) who suffered from ARF defined by the
widely accepted consensus and needed breathing support.
Interventions in the experiment group were NIV with a
standard or new-generation helmet independent of venti-
lation mode; breathing support strategies in the control
group included NIV or oxygen therapy with any kind
of noninvasive interface. The primary outcomes were
hospital mortality, intubation rate, and complications.
The secondary outcomes included the length of stay
in the intensive care unit (ICU), arterial blood gas ex-
change [including pH, the ratio of arterial oxygen partial
pressure to fractional inspired oxygen (PaO2/FiO2), and
partial pressure of carbon dioxide in the blood (PaCO2)]
and respiratory rate. Randomized and case-control trials
that met the eligible criteria were included, while cross-
over studies were excluded.
Search strategy
Two authors (QL and YG) performed a computerized
search of the Cochrane Library, PubMed, Ovid, and
Embase databases for articles published from inception
to June 2016. The search strategy was a combination of
keywords and terms as follows: helmet OR hood AND
mechanical ventilation OR noninvasive ventilation OR
oronasal mask OR facial mask OR nasal mask OR oxy-
gen therapy. The searches were restricted to studies on
humans without language limitations. The references of
all included articles were checked manually to identify
additional eligible studies. Duplicate articles were identi-
fied and deleted.
Eligibility criteria
We screened for relevant studies that adopted the stand-
ard or new-generation helmet as an interface for breathing
support. The inclusion criteria were as follow: (1) the main
objective was to compare the effect of helmet ventilation
with the control strategy, including randomized controlled
trials (RCTs) and case-control studies; (2) adult patients
with ARF; (3) outcomes were related to short-term effect
such as gas exchange or long-term effect such as hospital
mortality; (4) at least one outcome could be extracted.
The exclusion criteria were: (1) helmet was introduced for
prophylactic use; (2) trial subjects were postoperative
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patients, healthy volunteers, or simulators; (3) only a
meeting paper or abstract was published without the full
text; (4) studies without a control group; (5) editorials,
case reports, letters, reviews, news, comments, guidelines,
and meta-analyses. Checking of potentially eligible studies
was performed independently by two authors (QL and
YG), and in case of disagreement, both authors reviewed
the article together until a consensus was made [24] and a
third researcher (ZC) decided whether to include it or not.
Data extraction and quality assessment
General material and outcomes were extracted from the
selected articles. For dichotomous data (hospital mortal-
ity, intubation rate, and complications), number of
events and patients in each group were picked up as the
established protocol. For continuous data (gas exchange,
respiratory rate, length of stay in ICU), we extracted the
means, standard deviations, and the group sizes. The pa-
tient who refused intubation when meeting intubation
criteria was included in the intubation group, the other
data was extracted directly. To assess the possible risk of
bias for RCTs, we used the Cochrane Collaboration tool,
Table 8.5.a in the Cochrane Handbook for Systematic
Reviews of Interventions, for assessing the risk of bias
[25]. This tool covered six domains as follows: sequence
generation, allocation concealment, blinding of partici-
pants and personnel, blinding of outcome assessment, in-
complete outcome data, and selective outcome reporting.
Each domain was rated as “high risk”, “low risk” or
“unclear” of bias according to the relative information.
To assess the possible risk of bias for case-control trials,
we adopted the Newcastle-Ottawa scale (NOS), which fo-
cused on three categories: selection, comparability, and
exposure with each being awarded a maximum of nine
stars on items [26]. The judgements were made independ-
ently by two review authors (QL and YG). In case of dis-
agreement, it was resolved first by discussion and then by
consulting a third author (ZC) for arbitration.
Statistical analysis
We performed our meta-analysis including all studies.
For dichotomous outcomes, pooled odds ratio (OR) with
95 % confidence interval (CI) was estimated by the
Mantel-Haenszel method. For continuous outcomes,
pooled effect sizes were calculated by the inverse vari-
ance method and expressed as mean difference (MD)
with 95 % CI. If the homogeneity across studies was suf-
ficient, the analysis was performed using a fixed effect
model, whereas if not, a random effects model was used.
The heterogeneity across studies was tested by the I2
statistic, a quantitative measure of inconsistency [27, 28].
I2 values of 25–50 % indicated low, 50–70 % moderate,
and >75 % high heterogeneity [24]. We further conducted
subgroup analysis to explore possible explanations for
heterogeneity. A P value of less than 0.05 was considered
to be statistically significant for all analyses. Potential
publication bias was assessed by visual inspection of
the funnel plot in which the logarithms of ORs were plotted
against their standard errors. Statistical analyses were
performed with Review Manager 5.3 software (Cochrane
Collaboration, Oxford, UK). We adopted Begg’s and Egger’s
tests to evaluate the publication bias quantitatively and esti-
mated further using a trim and fill method if necessary by
STATA 12.0 (Stata Corp, College Station, TX, USA).
Results
Literature search and study identification
We found 310 articles according to the electronic search
strategy and one additional study was added from the
reference list of one article. The identifying process was
shown in Fig. 1. A total of 246 studies were excluded ac-
cording to the inclusion and exclusion criteria after
screening titles and abstracts for relevance, patients re-
cruited, and article type. Fifty-four studies were excluded
after examination of the full text. Finally, 11 studies in-
volving 621 patients, with six RCTs [15, 16, 29–32] and
five case-control studies [14, 17, 20, 33, 34], were
included for the meta-analysis. These studies recruited
patients admitted to ICUs [14, 15, 20, 29–32, 34], emer-
gency departments [33], high dependency units [16], and
departments of hematology [17] in different countries:
Italy [14–17, 20, 34], Turkey [29, 30], Brazil [31], America
[32], and France [33]. The characteristics of the studies
are shown in Table 1. Eight studies performed NIV
through helmet with pressure support ventilation (PSV)
[14, 15, 20, 29–32, 34] and three with continuous posi-
tive airway pressure (CPAP) [16, 17, 29]. In the control
group, the interfaces were facial mask in nine studies
[14, 17, 20, 29–34], oronasal mask [15] and Venturi
mask [16] in one study, respectively.
Quality assessment
The results of quality assessment were shown in Table 2
and Table 3. As shown in Table 2, the scores of case-
control trials ranged from five to eight stars, more than
four stars were defined as high-quality. All studies re-
ported the clear definition of cases and controls. All
cases in each study were included during a certain
period, in certain medical centers, and thus confirm the
representativeness of cases. These items were awarded
stars. Four historical controlled studies used different
methods to ascertain exposure for cases and controls
and the samples might be from different population be-
cause of inclusion from different periods [17, 20, 33, 34].
In the control group, one study with shorter NIV dur-
ation [17] and one with lower pressure support [20], we
considered insufficient for additional control factors. No
study mentioned the nonresponse rate. All of these
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conditions were not awarded stars. For the RCTs, as
shown in Table 3, most of domains were evaluated as
low risk of bias. Most notably, blinding of participants
and personnel was not possible in these trials because of
the nature of the intervention, i.e., NIV with a helmet or
not, therefore performance bias was considered as high
risk in all the studies. For the outcomes of interest, such
as mortality, the outcome assessment was not affected
by blinding or not, we evaluated the detection bias as
low risk.
Effect of NIV with a helmet on hospital mortality
Seven studies including 449 patients reported hospital
mortality. The pooled results are shown in Fig. 2a. The
hospital mortality was 17.53 % (37/211) in the helmet
NIV group compared to 30.67 % (73/238) in the control
group. Pooled results showed the helmet was associated
with lower hospital mortality (OR 0.43, 95 % CI 0.26 to
0.69, P = 0.0005). There was no heterogeneity found
across studies within and between subgroups according
to study design.
Effect of NIV with a helmet on intubation rate,
complications, and length of ICU stay
Ten studies recruiting 599 patients offered information
about intubation. NIV with a helmet significantly reduced
the intubation rate (16.85 % versus 37.26 %) and the OR
was 0.32 with a 95 % CI from 0.21 to 0.47 (P < 0.00001),
the heterogeneity was low with I2 41 % (P = 0.09) (Fig. 2b).
Overall complications in the helmet NIV group were less
than the control group with OR 0.60 (95 % CI from 0.40
to 0.92, P = 0.02) (Fig. 2c). Only four articles expressed the
data of length of ICU stay in the form of mean ± standard
deviation. NIV with a helmet did not affect the length of
ICU stay (MD −1.27, 95 % CI: −3.12 to 0.58, P = 0.18)
(Fig. 2d).
Effect of NIV with a helmet on gas exchange and
respiratory rate
NIV with a helmet had the same effect on the improve-
ment of PaO2/FiO2 and arterial pH as the control strategy
(P > 0.05) (Fig. 3a, b). PaCO2 in the helmet NIV group was
not higher than the control group, but the heterogeneity
Search Strategy
Electronic literature search in Cochrane library, PubMed, Ovid, and 
Embase: 310
Excluded after screening titles and abstracts: 246
• Case report 6
• Pediatric patients 
• Not relevant 235
Articles identified as relevant: 65
Retrieved for detailed evaluation, included in qualitative synthesis
Added after manual search of bibliographies: 1
Studies included in this meta-analysis: 11
6 RCTs and 5 case controlled trials 
Studies with available outcomes: 11
• Hospital mortality 7
• Intubation rate 10
• Complications 9
• Length of ICU stay 4
• Gas exchange 7
• Respiratory rate 6
Excluded according to the full text: 54
• Review 7
• Study design 30
• Prophylactic or postoperative use 10
• Healthy volunteers or simulators 5
















Fig. 1 Flow chart showing the selection of studies in this meta-analysis
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Table 2 Quality assessment of case-control studies included by NOS

























Antonelli 2002 [14] ★ ★ ★ ★ ★ ★ ★ ★ - 8
Principi 2004 [17] ★ ★ - ★ ★ - ★ - - 5
Antonelli 2004 [20] ★ ★ - ★ ★ - ★ - - 5
Tonnelier 2003 [33] ★ ★ - ★ ★ ★ ★ - - 6
Rocco 2004 [34] ★ ★ - ★ ★ ★ ★ - - 6
NOS Newcastle-Ottawa scale; ★ the quality met the criterion of this specific item, - the item was not qualified to be awarded a star



















33 66 Gas exchange, respiratory rate, intubation
rate, length of NIV, level of pressure support,
ICU stay and hospital mortality, complications








39 41 Respiratory rate, dysponea score, intubation
rate, level of pressure support, hemodynamics,
complications









40 41 Gas exchangea, intubation rate, hospital stay
and mortality, complications









17 17 Gas exchange, intubation rate, PTS, length
of NIV, complications








33 33 Gas exchange, respiratory rate, intubation
rate, length of NIV, level of pressure support,
hemodynamics, ICU stay, ICU and hospital
mortality, complications






15 15 Gas exchange, respiratory rate, hemodynamics,
ICU stay, PTS, intubation rate, complications






25 23 Gas exchangea, respiratory rateb, PTS,
complications, ICU stayb, length of NIV,
hospital mortality






20 20 Gas exchange, respiratory rateb, intolerance
to the interface, length of ICU stayb, time of
ventilator assistance




44 39 Respiratory rateb, intubation rate, length of
NIV, level of pressure support, ICU and
hospital stayb, hospital and 90d mortality,
complications, ventilator-free days









11 11 Glasgow coma scale, gas exchange, respiratory
rate, complications, hospital mortality








19 19 Gas exchange, respiratory rate, intubation rate,
length of NIV, level of pressure support, ICU
stay, ICU and hospital mortality, complications
ARF acute respiratory failure, COPD chronic obstructive pulmonary disease, PSV pressure support ventilation, NIV noninvasive ventilation, ICU intensive care unit,
AECOPD exacerbation of COPD, CPAP continuous positive airway pressure, PTS patient tolerance scale, RCT randomized control trail, ARDS acute respiratory
distress syndrome
aOutcome presented in figure form
bOutcome presented as interquartile range
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was not perfect with I2 equal to 72 % (P = 0.11) (Fig. 3c).
The respiratory rate was similar in both groups and MD
was −0.59 (95 % CI: −1.68 to 0.51, P = 0.29) (Fig. 3d).
Subgroup analysis
Trials both designed in randomization and case-control,
showed use of a helmet was associated with lower hospi-
tality mortality (Fig. 2). As shown in Table 4, further
subgroup analysis according to the type of ARF found
that NIV with a helmet reduced mortality mainly in the
patient group with hypoxemic ARF with OR 0.38 (0.22,
0.65) (P = 0.0005), and helmet with both CPAP and PSV
could reduce mortality (P < 0.05). NIV with a helmet
could decrease the intubation in both hypercapnic and
hypoxemic ARF patients independent of the ventilation
mode (P < 0.05). Fewer complications occurred in the
subgroup patients with hypercapnic ARF (P < 0.05).
PaCO2 could be decreased further in hypercapnic patients
or ventilation with PSV (P < 0.00001), the effect of a hel-
met on the continuous outcomes (the ICU stay, oxygen-
ation, pH, and respiratory rate) were not influenced by
type of ARF and ventilation mode, a helmet improved pH
mainly shown by case-control trials (P = 0.04) (Table 5), in
addition interfaces used in the control group did not affect
the final result significantly (Tables 4 and 5).
Publication bias
Visual inspection of the funnel plot indicated a little
asymmetry for the effect of NIV with a helmet on hos-
pital mortality (Fig. 4). The publication bias was signifi-
cant when estimated by Egger’s test (P = 0.014) and was
not consistent when estimated by Begg’s test (P = 0.072).
Nevertheless, the pooled results, tested further via trim
and fill method, were credible and steady.
Discussion
To our knowledge, this is the first meta-analysis to in-
vestigate the effect of NIV with a helmet on ARF pa-
tients. We found that NIV with a helmet significantly
reduced hospital mortality, tracheal intubation rate, and
complications compared with the control techniques.
And subgroup analyses found NIV with a helmet, es-
pecially in PSV mode, could decrease the PaCO2 in
hypercapnic patients, but did not increase PaCO2 in
the overall group. The helmet was as efficient as a
mask on shortening the length of ICU stay, improving
oxygenation and pH.
NIV delivered breathing support without the use of
endotracheal or tracheostomy tube. The interface be-
tween the patients and NIV ventilators included nasal,
oronasal, and facial mask. These noninvasive interfaces
differentiated NIV from invasive mechanical ventilation,
and maintained the airway protection mechanisms and
the patient’s ability to swallow. Well- cooperated NIV
decreased mortality in selected patients [1, 2, 35–37].
However, patient discomfort and complications might
limit continuous application of NIV [7], further decrease
its efficacy, and even increase mortality. Some of these
complications and discomfort were related to the mask
[7–9, 38]. In order to improve tolerability for patients, a
transparent helmet made from latex-free polyvinyl chloride
was developed [13].
This meta-analysis has shown NIV with a helmet re-
duced hospital mortality further compared with other
masks in both RCTs and case-control trials, which
meant the helmet itself had an effect on the patient’s
survival. This effect might be attributed to the unique
advantages that masks did not possess. First, the helmet
allowed patients to freely drink, communicate and ex-
pectorate. It improved clearance of sputum and collabor-
ation with caregivers without interference of the NIV.
Second, the helmet was a better tolerated interface, pa-
tients need not try hard to cater to the interface as with
a mask. The patient tolerance scale in the helmet group
was remarkably higher than in the facial mask control
group [14, 17, 29, 39]. Better tolerance allowed a longer
continuous application [14, 31] and increased the suc-
cess rate of NIV [40]. In fact, no patients failed NIV as a
result of claustrophobia, discomfort, or pain related to a
helmet while 38 % patients might have a failed NIV
owing to a mask [14], which would increase hospital
mortality. Third, the helmet could be applied to any
Table 3 Quality assessment of RCTs included by the Cochrane Collaboration tool












Pisani 2015 [15] Low Low High Low Low Low
Brambilla 2014 [16] Low Low High Low Low Low
Ali 2011 [29] Unclear Unclear High High Low Low
Özlem 2015 [30] Unclear Unclear High High Low Low
Antonaglia 2011 [31] Low Low High High Unclear Low
Patel 2016 [32] Low Low High Low Low Low
Low low risk of bias, High high risk of bias, Unclear unclear risk of bias according to the relative information
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patient regardless of their face contour. During the
course of NIV with a mask, 24–64 % of patients had to
change to another type of mask [12, 41] and the most
common reason for non-adaptation to the mask was the
shape of the face [41, 42]. Unlike the mask, the helmet
could also be used in difficult anatomical situations such
Fig. 2 Effect of NIV with a helmet on primary outcomes and length of ICU stay. The helmet NIV group represents patients receiving NIV with a
helmet, the control group represent patients receiving NIV with a mask or oxygen therapy with a mask. Vertical solid line null effect, boxes and
horizontal lines outcome in the corresponding study and 95 % CI, filled rhombic boxes overall effect size. a Effect of NIV with a helmet on hospital
mortality; b effect of NIV with a helmet on intubation rate; c effect of NIV with a helmet on complications; d effect of NIV with a helmet on
length of ICU stay. CI confidence interval, ICU intensive care unit, IV inverse variance method, NIV noninvasive ventilation, M-H Mantel-Haenszel
method, SD standard deviation
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Fig. 3 Effect of NIV with a helmet on the gas exchange and respiratory rate. The helmet NIV group represents patients receiving NIV with a
helmet, the control group represent patients receiving NIV with mask or oxygen therapy with mask. Vertical solid line null effect, boxes and
horizontal lines outcome in the corresponding study and 95 % CI, filled rhombic boxes overall effect size. a Effect of NIV with a helmet on
oxygenation; b effect of NIV a with helmet on pH; c effect of NIV with a helmet on PaCO2; d effect of NIV with a helmet on respiratory rate. CI
confidence interval, IV inverse variance method, NIV noninvasive ventilation, PaCO2 partial pressure of carbon dioxide in arterial blood, P/F the
ratio of partial pressure of oxygenation in arterial blood to fraction of inspired oxygenation, SD standard deviation,
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as in edentulous or facial trauma patients [13]. In short,
good amenity, better tolerance, and universal application
of the helmet ensured NIV was better used and reduced
intubation (as shown in this analysis in Fig. 2b), which
might contribute to preventing ventilator-associated
pneumonia and decreasing hospital mortality [43].
An exciting finding was that the helmet could reduce
the mortality of patients with hypoxemic ARF. Some stud-
ies aimed to explore applying NIV through a mask in this
kind of patient, however, the results were disappointing,
successful treatment was lower with a limited effect on
the prognosis [43–46]. This might be relevant to the dif-
ferent breathing patterns in hypoxemic ARF and hyper-
capnic ARF patients. In patients with hypoxemic ARF,
mouth breathing was more common, with unavoidable air
leaks although a facial or whole face mask was used [47].
The helmet improved tolerance and increased efficient
ventilation, which was very important for patients with
hypoxemic ARF. The continuous application of NIV was
crucial in the onset phases of ARF, which otherwise might







I2 (%) P value for
heterogeneity




Hypercapnic 2 8/58 11/56 0 0.8 0.65 [0.28, 2.06] 0.81/0.42
Hypoxemic 5 29/153 62/182 0 0.97 0.38 [0.22, 0.65] 3.49/0.0005
Ventilation mode in the experimental group
CPAP 2 6/57 15/58 0 0.79 0.30 [0.10, 0.89] 2.17/0.03
PSV 5 31/154 58/180 0 0.77 0.46 [0.27, 0.79] 2.8/0.005
Interfaces used in the control group
Facial mask 6 35/171 66/197 0 0.97 0.45 [0.27, 0.74] 3.12/0.002
Venturi mask 1 2/40 7/41 NA NA 0.26 [0.05, 1.32] 1.63/0.1
Intubation rate
Type of ARF
Hypercapnic 5 15/132 29/132 0 0.42 0.42 [0.20, 0.85] 2.41/0.02
Hypoxemic 5 33/153 88/143 61 0.03 0.28 [0.17, 0.45] 5.16/<0.0001
Ventilation mode in the experimental group
CPAP 2 10/57 34/58 42 0.19 0.16 [0.07, 0.36] 4.28/<0.0001
PSV 8 38/228 83/256 30 0.19 0.39 [0.25, 0.62] 4.05/<0.0001
Interfaces used in the control group
Facial mask 8 42/206 89/232 29 0.2 0.39 [0.25, 0.61] 4.16/<0.0001
Oronasal mask 1 0/39 2/41 NA NA 0.20 [0.01, 4.30] 1.03/0.3
Venturi mask 1 6/40 26/41 NA NA 0.32 [0.21, 0.47] 5.56/<0.0001
Complications
Type of ARF
Hypercapnic 3 20/97 35/97 77 0.01 0.45 [0.23, 0.86] 2.42/0.02
Hypoxemic 6 28/164 48/193 17 0.30 0.76 [0.43, 1.32] 0.98/0.33
Ventilation mode in the experimental group
CPAP 3 7/68 7/69 57 0.10 1.01 [0.36, 2.89] 0.03/0.98
PSV 6 41/193 76/221 46 0.10 0.55 [0.34, 0.87] 2.35/0.06
Interfaces used in the control group
Facial mask 7 31/182 72/208 25 0.24 0.40 [0.24, 0.67] 3.49/0.0005
Oronasal mask 1 11/39 9/41 NA NA 1.40 [0.51, 3.86] 0.64/0. 52
Venturi mask 1 6/40 2/41 NA NA 3.44 [0.65, 18.2] 1.45/0.15
NIV noninvasive ventilation, OR odds ratio, CI confidence interval, ARF acute respiratory failure, CPAP continuous positive airway pressure, PSV pressure support
ventilation, NA not applicable
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Table 5 Subgroup analysis - the effect on secondary outcomes
No. of studies Patients (n) H/C I2 (%) P value for heterogeneity MD 95 % CI Overall effect Z/P value
Length of ICU stay
Type of ARF
Hypercapnic 2 48/48 0 0.69 −1.22 [−3.47, 1.04] 1.06/0.29
Hypoxemic 2 52/85 0 0.37 −1.38 [−4.63, 1.88] 0.83/0.41
Ventilation mode in the experimental group
CPAP 1 15/15 NA NA −1.10 [−3.43, 1.23] 0.93/0.35
PSV 3 85/118 0 0.63 −1.56 [−4.63, 1.50] 1/0.32
Study design
Case-control trial 3 85/118 0 0.63 −1.56 [−4.63, 1.50] 1/0.32
RCT 1 15/15 NA NA −1.10 [−3.43, 1.23] 0.93/0.35
Oxygenation (PaO2/FiO2)
Type of ARF
Hypercapnic 3 68/68 0 0.38 1.23 [−9.32, 11.78] 0.23/0.38
Hypoxemic 4 80/113 59 0.06 2.37 [−23.34, 28.08] 0.18/0.86
Ventilation mode in the experimental group
CPAP 2 28/28 53 0.15 −66.01 [−130.73, −1.28] 2/0.05
PSV 5 120/153 0 0.59 2.96 [−6.91, 12.83] 0.59/0.56
Study design
Case-control trial 5 113/146 49 0.1 4.16 [−22.55, 14.22] 0.44/0.66
RCT 2 35/35 0 0.33 3.57 [−7.95, 15.09] 0.61/0.54
pH
Type of ARF
Hypercapnic 3 68/68 16 0.3 −0.00 [−0.02, 0.02] 0.01/1
Hypoxemic 3 63/96 28 0.25 −0.02 [−0.04, 0.00] 1.59/0.11
Ventilation mode in the experimental group
CPAP 1 11/11 NA NA −0.04 [−0.11, 0.03] 1.19/0.24
PSV 5 120/153 30 0.22 −0.01 [−0.02, 0.01] 0.74/0.46
Study design
Case-control trial 4 96/129 0 0.43 −0.02 [−0.04, −0.00] 2.02/0.04
RCT 2 35/35 0 0.73 0.01 [−0.01, 0.03] 0.85/0.4
PaCO2
Type of ARF
Hypercapnic 3 68/68 0 0.5 6.15 [4.17, 8.13] 6.08/<0.00001
Hypoxemic 3 63/96 0 0.7 −1.76 [−5.13, 1.60] 1.03/0.30
Ventilation mode in the experimental group
CPAP 1 11/11 NA NA −1.40 [−16.96, 14.16] 0.18/0.86
PSV 5 120/153 77 0.002 4.18 [2.46, 5.90] 4.76/<0.00001
Study design
Case-control trial 4 96/129 61 0.05 0.15 [−2.90, 3.20] 0.1/<0.92
RCT 2 35/35 0 0.39 5.92 [3.85, 7.98] 5.62/<0.00001
Respiratory rate
Type of ARF
Hypercapnic 3 87/89 23 0.27 −0.56 [−1.85, 0.74] 0.84/0.4
Hypoxemic 3 63/96 65 0.06 0.58 [−3.52, 4.69] 0.28/0.78
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forebode NIV failure and life-threatening consequences
[14, 48–50]. It should be noted that this finding did not
mean NIV with a helmet had no effect on the mortality
of patients with hypercapnic ARF, since only two stud-
ies with small sample sizes had reported this variable in
this meta-analysis [20, 30]; this question warrant further
investigation.
The pooled effect indicated that NIV through a helmet
decreased complications and intubation rate dramatic-
ally. The helmet was a transparent plastic hood, which
did not come into contact with the patient’s face, espe-
cially the nose bridge and did not cause skin lesions
[13]. With this device, air leaks were localized around
the neck, which prevented eye irritation and conjunctiv-
itis. The fixation system was not as complicated as the
traditional mask. A simplified fixation system should carry
a lower risk of cutaneous lesions. The new-generation hel-
met, characterized by an annular openable ring placed
underneath an inflatable cushion, further reduced discom-
fort and axillary skin lesions caused by padded armpit
braces in a standard helmet, so complications might only
be confined to the neck [51]. Fewer complications aided
the patients’ adherence to the NIV and increased the suc-
cess rate although the effect on reducing complications was
mainly observed in observational studies and larger RCTs
are still needed to confirm the results. In addition, the use
of specific ventilator settings with the fastest pressurization
rate, higher inspiratory and expiratory pressures could im-
prove patient ventilator interaction [52, 53]. All of these key
issues prevented some patients from intubation.
Table 5 Subgroup analysis - the effect on secondary outcomes (Continued)
Ventilation mode in the experimental group
CPAP 1 11/11 NA NA 6.00 [−0.08, 12.08] 1.93/0.05
PSV 5 139/174 0 0.44 −0.81 [−1.92, 0.30] 1.42/0.15
Study design
Case-control trial 4 96/129 57 0.07 0.07 [−1.45, 1.60] 0.1/0.92
RCT 2 54/56 0 0.98 −1.29 [−2.86, 0.28] 1.61/0.11
Interfaces used in the control group
Facial mask 5 111/144 51 0.08 −0.49 [−1.66, 0.69] 0.81/0.42
Oronasal mask 1 39/41 NA NA −1.26 [−4.28, 1.76] 0.82/0.41
H/C helmet/control, MD mean difference, CI confidence interval, ICU intensive care unit, ARF acute respiratory failure, CPAP continuous positive airway pressure,
PSV pressure support ventilation, high quality randomized controlled trial, PaO2/FiO2 the ratio of the partial pressure of oxygen in arterial blood to the inspired
oxygen fraction, pH potential of hydrogen, PaCO2 partial pressure of carbon dioxide, NA not applicable
Fig. 4 Funnel plots to assess publication bias regarding the effect of NIV with a helmet on hospital mortality. SE standard error, OR odds ratio
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Our analysis informed that NIV via a helmet was as ef-
fective as existing masks in gas exchange although respira-
tory rates, reflecting the degree of dyspnea to a certain
extent, did not decrease noticeably. NIV with a helmet
could improve oxygenation by delivering high oxygen
concentration, unloading respiratory muscles, recruiting
alveoli and increasing functional lung volumes, which was
no different from NIV with other interfaces or invasive
mechanical ventilation [54]. Moreover, the helmet further
reduced leaks in contrast with masks. After all, the aim of
introducing the helmet, still a noninvasive interface, was
to reduce complications and increase patient comfort, to
achieve better use of NIV and improve the prognosis,
not just to improve gas exchange further. In theory, the
helmet predisposed to CO2 rebreathing, meanwhile the
CO2 concentration within the interface depended on
the patient’s CO2 production and could be minimized
by specific settings including high fresh gas flow or
higher inspiratory pressure [55–57]. NIV through a hel-
met might take a longer time to achieve the target level
of pressure support due to its larger inner volume. At a
lower level of pressure support, the helmet might not
decrease the work of breathing and has a restricted effect
on respiratory rate.
In the past three decades, NIV played a critical role in
the treatment of ARF, especially using CPAP and PSV.
From a physiological rationale level, PSV could provide
more benefit than CPAP. Regrettably, PSV has not been
found to offer any advantage in terms of intubation or
mortality [58]. As shown in the subgroup analysis by
ventilation mode, both CPAP and PSV with a helmet
could reduce the mortality and intubation rate, although
PaCO2 decreased mainly in the subgroup with PSV, and
improve prognosis. This result was similar with the find-
ings in patients with cardiogenic pulmonary edema [58].
Several limitations should be considered when interpret-
ing our findings. First, because of the paucity of studies in
this novel strategy, both RCTs and case-control trials were
included. Fortunately, the results were substantially con-
firmed by pooled RCTs or case-control trials separately
with low heterogeneity among the studies. Second, patients
recruited in the included studies suffered from hypercapnic
or hypoxemic ARF and were not highly consistent with
each other. Third, the ventilation characteristics were not
homogeneous, some were in CPAP mode, others in PSV,
and the interface in the control group involved facial, nasal,
oronasal and Venturi masks. Fourth, high heterogeneity
existed across the studies for the variable PaCO2 (I
2 equal
to 72 %), this could be partly explained by the ARF type. In
addition, publication bias might exist measuring by Begg’s
and Egger’s test, but the final results were credible and
steady tested by the trim and fill method, which tend to be
more efficient when limited studies are included in a meta-
analysis [59]. Finally, all of the included RCTs had high risk
of performance bias attributed to the dramatic difference
between a helmet and mask, which made it impossible for
participants and personnel blinding to the interface and
might influence the outcomes in a certain extent, we sug-
gest that more attention should be paid to this key issue in
future researches.
Conclusions
In conclusion, this meta-analysis indicated NIV with a hel-
met improved the prognosis, reduced the requirement of
intubation and complications. The helmet was as effective
as the mask in gas exchange despite no additional advan-
tage. It should be noted that there is not sufficient scien-
tific evidence to recommend it in designated patients due
to the limited number of trials available. Large RCT stud-
ies are still needed to provide more robust evidence.
Key messages
 NIV with a helmet improved the prognosis, reduced
the requirement of intubation and complications. The
helmet was as effective as the mask in gas exchange
although without any additional advantage.
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